The Point of Care Technology Research Network (POCTRN) based at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) selects LifeGene-Biomarks, Inc. to participate in the 2022 Commercialization Readiness Assessment and Accelerator of Solutions in Healthcare (CRAASH) program.

CRAASH (see https://craash.org) is a 12-week program that facilitates the commercialization of healthcare innovations being developed by teams from academic labs and start-ups. 

CRAASH was developed more than 5 years ago with the support of the NIH and NSF. Building on the iCorps Program fundamentals, teams formulate business hypotheses which are tested by engaging directly with more than 100 stakeholders to develop a validated business model. It focuses on helping teams de-risk projects by addressing the unique challenges in commercializing healthcare innovations and is facilitated by industry veterans and experts working in close collaboration with teams.